Impact of the Alzheimer's Disease Neuroimaging Initiative, 2004 to 2014

Abstract

Introduction The Alzheimer’s Disease Neuroimaging Initiative (ADNI) was established in 2004 to facilitate the development of effective treatments for Alzheimer’s disease (AD) by validating biomarkers for AD clinical trials. Methods We searched for ADNI publications using established methods. Results ADNI has (1) developed standardized biomarkers for use in clinical trial subject selection and as surrogate outcome measures; (2) standardized protocols for use across multiple centers; (3) initiated worldwide ADNI; (4) inspired initiatives investigating traumatic brain injury and post-traumatic stress disorder in military populations, and depression, respectively, as an AD risk factor; (5) acted as a data-sharing model; (6) generated data used in over 600 publications, leading to the identification of novel AD risk alleles, and an understanding of the relationship between biomarkers and AD progression; and (7) inspired other public-private partnerships developing biomarkers for Parkinson’s disease and multiple sclerosis. Discussion ADNI has made myriad impacts in its first decade. A competitive renewal of the project in 2015 would see the use of newly developed tau imaging ligands, and the continued development of recruitment strategies and outcome measures for clinical trials.

On the early diagnosis of Alzheimer's Disease from multimodal signals: A survey

“…is also in progress. The review of Weiner et al [313] highlights the major findings of the ADNI database up to 2015. Besides, ADNI has also encouraged the creation of other datasets of similar characteristics [313].…”

The Worldwide Alzheimer's Disease Neuroimaging Initiative: An update

“…The cores operate under the auspices of an executive committee, with additional input from industry partners [1], and are hosted by .56 facilities around the United States and Canada. Their accomplishments have been considerable and diverse, and they have gone beyond the original goals of the initiative: impacting the industry-wide practice of open data-sharing, discovering genes that promote AD risk, and helping to establish other initiatives aimed at developing therapies for dementia [3].…”

Collaborative efforts to prevent Alzheimer's disease

“…ADNI evolved from a US-and Canada-based clinical research study aimed at identifying and validating preclinical and prodromal biomarkers of AD to the pre-eminent multinational research program supporting advances in treatment and prevention. ADNI data have been instrumental in demonstrating that the disease begins decades before symptoms appear and progresses relentlessly toward dementia (2). These studies provided the rationale for preventive approaches that begin treatment in the earliest, preclinical stages of disease.…”